Industry News

Allegro initiates phase 2 study of vitreomacular traction therapy

Allegro Ophthalmics has initiated a phase 2 study of ALG-1001 in patients with vitreomacular traction, according to a press release.

The placebo-controlled, randomized, double-masked, dose-ranging study will evaluate the safety and efficacy of intravitreal injections of ALG-1001 in patients with VMT. The primary efficacy endpoint is release of VMT as determined by optical coherence tomography images. Secondary endpoints include the observation of nonsurgical closure of full-thickness macular holes, best corrected visual acuity improvement over baseline and forgone need for pars plana vitrectomy, according to the release.

Patients are being enrolled outside the United States at multiple sites.

ALG-1001 is an integrin peptide therapy that targets integrins, which play a role in cell signaling and regulating cellular shape, motility and the cell cycle. The therapy collectively turns off the production, reduces the leakage and inhibits the growth of aberrant blood vessels. ALG-1001 also targets the key integrin receptor site at the vitreoretinal interface to release cellular adhesion between the vitreous and the retina, the release said.

Allegro Ophthalmics has initiated a phase 2 study of ALG-1001 in patients with vitreomacular traction, according to a press release.

The placebo-controlled, randomized, double-masked, dose-ranging study will evaluate the safety and efficacy of intravitreal injections of ALG-1001 in patients with VMT. The primary efficacy endpoint is release of VMT as determined by optical coherence tomography images. Secondary endpoints include the observation of nonsurgical closure of full-thickness macular holes, best corrected visual acuity improvement over baseline and forgone need for pars plana vitrectomy, according to the release.

Patients are being enrolled outside the United States at multiple sites.

ALG-1001 is an integrin peptide therapy that targets integrins, which play a role in cell signaling and regulating cellular shape, motility and the cell cycle. The therapy collectively turns off the production, reduces the leakage and inhibits the growth of aberrant blood vessels. ALG-1001 also targets the key integrin receptor site at the vitreoretinal interface to release cellular adhesion between the vitreous and the retina, the release said.